(NASDAQ:ATON), Vatican City, Oct. 20, 2025 (GLOBE NEWSWIRE) — Enzo Villani, Chief Investment Officer of AlphaTON Capital (NASDAQ: ATON), has been invited to speak at the 10th Anniversary of the IASC World Changers Summit, held at the historic Casina Pio IV within Vatican City, home of the Pontifical Academy of Sciences. This prestigious gathering brings […]
(OtherOTC:AIMV),(OTC US:AIMV), NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) — via IBN – AI Maverick Intel Inc. (OTC: AIMV), a technology-driven innovator focused on redefining how businesses acquire and engage customers through artificial intelligence, today announced that effective Oct. 20, 2025, the Company's common shares will commence trading on the OTC Market under its new
(NASDAQ:APLS), Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR less-than or equal to0.5 g/g) achieved in one-third of patients and sustained through one year Two indirect treatment comparisons indicate that EMPAVELI was superior to iptacopan in reducing proteinuria and achieving the composite renal endpoint
Built on a vision of being lean, green and digital TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) — Humber River Health proudly marks the 10th anniversary of its Wilson Site, a decade since opening North America's first fully digital hospital and redefining the way healthcare is delivered in Canada. Since opening its doors on October 18,
(TSX:SJ), MONTREAL, Oct. 20, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ) (“Stella-Jones” or the “Company”) announced today the appointments of Ms. Renee Laflamme and Mr. Sean Donnelly to its Board of Directors. Ms. Laflamme is an accomplished executive with over 25 years of experience in the financial services and insurance sectors. She currently serves
(NASDAQ:AUTL), LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the first patient has been dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis (PMS).
Valhalla, N.Y., Oct. 20, 2025 (GLOBE NEWSWIRE) — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement consulting, today announced the impact of its 12th annual USI Gives Back campaign, an award-winning social responsibility program focused on supporting positive change in local communities. Throughout August and September, USI team members
(Other OTC:OTCM),(OTC US:OTCM),(Nasdaq First North Sweden:GIG-SDB),(Other OTC:GIGXF), NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced GiG Software PLC (Swedish Nasdaq First North Premier Growth Market: GIG SDB; OTCQX: GIGXF), a leading B2B iGaming technology company, has
(Other OTC:OTCM),(OTC US:OTCM),(TSX-V:MMA),(Other OTC:MDNGF), NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Midnight Sun Mining Corp (TSX-V: MMA; OTCQX: MDNGF), a mineral exploration and development company, has qualified to trade on the OTCQX(R) Best Market. Midnight
BioCryst to Report Third Quarter 2025 Financial Results on November 3 GlobeNewswire October 20, 2025 RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call